Detail akcie Aspire Bio Hldgs Rg online

Business Summary: Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Aspire Biopharma Holdings Inc revenues increased from $0K to $2K. Net loss increased from $3.6M to $19.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative expenses increase from $3.7M to $16M (expense), Interest Expense increase from $183K to $2.3M (expense).